Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP ...

Researchers at the ICR co-led a recent study showing that it is possible to reverse drug resistance and slow tumour progression in prostate cancer by targeting myeloid white blood cells. Tumours can ...

Jesse was two years old when he was diagnosed with B-cell acute lymphoblastic leukaemia, a type of blood and bone marrow ...

Dr Jessica May Hislop joined The Institute of Cancer Research as a Bioinformatician in the Houlston Lab in the Genetics and Epidemiology division. Together with her colleagues, she is working towards ...

Dr Jessica May Hislop joined The Institute of Cancer Research as a Bioinformatician in the Houlston Lab in the Genetics and Epidemiology division. Together with her colleagues, she is working towards ...

Scientists have created a prototype test that can predict which drug combinations are likely to work for cancer patients in as little as 24 to 48 hours. Their cutting-edge technique uses artificial ...

Our vision: We will transform the lives of cancer patients through world-class research and education, and by growing our impact on society. Video: ICR Chief Executive Kristian Helin gives an overview ...

The Institute of Cancer Research has outlined its position on a number of policy issues in scientific and medical research. Our statements can be read and downloaded below. You may also be interested ...

This Christmas, give the gift of research to help someone's mum, sister, nan, or friend survive cancer and look forward to spending more precious time with their loved ones. "I’m here to tell my story ...

Researchers have identified a key weakness in acute myeloid leukaemia, offering a promising new strategy to delay the progression of this aggressive blood cancer. The discovery focuses on disrupting ...

Image: The Man Van. Credit: The Man Van and The Royal Marsden NHS Foundation Trust. Mobile testing ‘Man Van’ can diagnose prostate cancer in at-risk groups earlier and more affordably than GPs, ...